Press Releases

2021.12.20

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

I-Mab today announced strategic leadership changes and a new governance initiative designed to facilitate its global pipeline development and accelerate its ongoing transformation towards an integrated global biopharma company.

2021.12.15

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab today announced that the CDE of China NMPA has approved the IND submission for the initiation of a phase 1 clinical study of the bispecific antibody TJ-CD4B in patients with solid tumors.

2021.12.14

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

Positive clinical activity was observed in heavily pretreated patients who had progressed on prior Anti-CD20 therapies.

2021.12.08

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer’s Disease

I-Mab today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimer's disease.

2021.12.07

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

I-Mab today announced that the Board of Directors of the Company approved a motion to pursue the listing of the Company’s ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited.

2021.12.03

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

I-Mab today announced that the first two patients have been dosed in the U.S. phase 2 dose expansion clinical study of its proprietary CD73 antibody uliledlimab in combination with atezolizumab in patients with ovarian cancer and other selected advanced or metastatic solid tumors.

2021.11.10

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa

I-Mab today announced that it has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group for the development, manufacturing and commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China.

2021.11.09

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC

I-Mab and ABL Bio today jointly announced preclinical data of their 4-1BB bispecific antibodies at the 2021 Society for Immunotherapy of Cancer Annual Meeting.

2021.11.08

I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab’s Innovative Pipeline at the 4th CIIE

I-Mab today announced that the Company has entered into a strategic collaboration with Roche Diagnostics to co-develop companion diagnostics solutions for I-Mab’s innovative pipeline, at the 4th CIIE in Shanghai.

2021.11.04

I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins’s Lymphoma at ASH 2021

I-Mab today announced that an abstract summarizing the most recent clinical data from an ongoing clinical trial of its differentiated CD47 antibody lemzoparlimab, will be presented at the 63rd American Society of Hematology Annual Meeting, taking place December 11 – 14, 2021.